Wall Street Zen Upgrades Synaptogenix (NASDAQ:TAOX) to Hold

Synaptogenix (NASDAQ:TAOX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Synaptogenix Stock Down 6.2%

Synaptogenix stock opened at $3.91 on Friday. Synaptogenix has a 52-week low of $1.84 and a 52-week high of $11.98. The company has a market cap of $29.13 million, a P/E ratio of -0.19 and a beta of 1.99. The business has a 50-day simple moving average of $4.43 and a two-hundred day simple moving average of $6.09.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.